Categories AlphaGraphs, Analysis, Retail
Ross Stores stock falls on holiday season worries despite upbeat Q3 results
Off-price retail apparel operator Ross Stores (ROST) reported a 23% jump in earnings for the third quarter helped by higher sales and the benefit of tax reform. The company raised its earnings guidance for the fourth quarter and fiscal 2018. However, the stock inched down over 7% in the premarket session on holiday season worries.
With sales increasing by 7% to $3.55 billion, earnings climbed 23% to $338 million or $0.91 per share. Comparable store sales rose 3% compared to the previous year’s gain of 4%.
Operating margin was 12.4%, down from last year, as higher merchandise margin was more than offset by increases in freight costs and this year’s wage investments.
Looking ahead into the fourth quarter, the company still expects same-store sales growth of 1% to 2%. Earnings guidance was lifted to the range of $1.09 to $1.14 per share from the prior estimate range of $1.02 to $1.07 per share. The revised earnings estimate includes a one-time, non-cash benefit of about $0.07 per share related to the favorable resolution of a tax matter.
For fiscal 2018, Ross Stores raised its earnings outlook to a range of $4.15 to $4.20 per share from the previous forecast range of $4.01 to $4.10 per share. As entering this year’s holiday season, the company expects another fiercely competitive retail environment.
During the third quarter, the Dublin, California-based company bought back 2.9 million shares of common stock for an aggregate of $278 million. The company remained on track to buy back a total of $1.075 billion in common stock during fiscal 2018.
Shares of Ross Stores ended Monday’s regular trading session down 4.29% at $91.19 on the Nasdaq. The stock has risen over 13% in the year so far and over 26% in the past year.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on